Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 1:32 AM
Ignite Modification Date:
2025-12-25 @ 1:32 AM
NCT ID:
NCT00590694
Eligibility Criteria:
Inclusion Criteria:
* Neovascular age-related macular degeneration patients over age 50
* Presence of a pigment epithelial detachment on optical coherence tomography
* Initial or recurrent disease
* Previous treatment allowed
* Visual acuity between Snellen 20/40 - 20/400
Exclusion Criteria:
* More than three previous treatments with PDT or other radiation/laser therapy
* Previous vitrectomy or other AMD surgical intervention
* Severe scarring or severe concurrent ocular disease (uncontrolled glaucoma)
Patients eligible for the study are randomized into one of two groups. Group 1 receives injections of ranibizumab until retinal edema is resolved. Group 2 receives ranibizumab injections until both retinal edema and the PED are resolved. Study duration is one year with visits once per month.
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
50 Years
Study:
NCT00590694
Study Brief:
Protocol Section:
NCT00590694